FIGURE 1.

Flow of patients through the study from enrollment to treatment allocation and inclusion in the propensity score–stratified analysis set. ^aEarly switchers were defined as patients for whom rivaroxaban was planned, but who initially received heparin or fondaparinux for ≥2‐14 days, a VKA for 1‐14 days, or both before switching to rivaroxaban. This patient group was ineligible for the safety analysis set. HIV, human immunodeficiency virus; VKA, vitamin K antagonist